Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 5/2022

09.01.2022 | Review Article

Bacterial driver–passenger model in biofilms: a new mechanism in the development of colorectal cancer

verfasst von: J. Xing, Y. Fang, W. Zhang, H. Zhang, D. Tang, D. Wang

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) is a heterogeneous disease of the intestinal epithelium and ranks the third largest diagnosed malignancy in the world. Many studies have shown that the high risk of CRC is believed to be related to the formation of biofilms. To prove causation, it will be significant to decipher which specific bacteria in biofilms initiate and maintain CRC and fully describe their underlying mechanisms. Here we introduce a bacterial driver–passenger model. This model added a novel and compelling angle to the role of microorganisms, putting more emphasis on the transformation of bacterial composition in biofilms which play different roles in the development of CRC. In this model, bacterial drivers can initiate the formation of CRC through genotoxicity, while bacterial passengers maintain the CRC process through metabolites. On the basis of these pathogens, we further turned our attention to strategies that can inhibit and eradicate these pathogenic biofilms, with the aim of finding new ways to hinder colorectal carcinogenesis.
Literatur
1.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–32.PubMed
2.
3.
Dai Z, Zhang J, Wu Q, Chen J, Liu J, Wang L, et al. The role of microbiota in the development of colorectal cancer. Int J Cancer. 2019;145(8):2032–41.PubMedPubMedCentral
4.
Li S, Konstantinov SR, Smits R, Peppelenbosch MP. Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med. 2017;23(1):18–30.PubMed
5.
Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359(6375):592–7.PubMedPubMedCentral
6.
Tytgat H, Nobrega F, van der Oost J, Vos de Tim WJ. Bowel biofilms: tipping points between a healthy and compromised gut? Trends Microbiol. 2019;27(1):17–25.PubMed
7.
Matsuo K, Ota H, Akamatsu T, Sugiyama A, Katsuyama TJG. Histochemistry of the surface mucous gel layer of the human colon. Trends Microbiol. 1997;40(6):782–9.
8.
Sicard J, Le Bihan G, Vogeleer P, Jacques M, Harel J. Interactions of intestinal bacteria with components of the intestinal mucus. Front Cell Infect Microbiol. 2017;7:387.PubMedPubMedCentral
9.
Lappin-Scott H, Costerton JW. Bacterial biofilms and surface fouling. Biofouling. 1989;1(4):323–42.
10.
Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9(1):522–54.PubMed
11.
Stoodley P, Sauer K, Davies D, Costerton JJ. Biofilms as complex differentiated communities. Ann Rev Microbiol. 2002;56:187–209.
12.
Dalton HM, Goodman AE, Marshall KC. Diversity in surface colonization behavior in marine bacteria. J Ind Microbiol. 1996;17(3):228–34.
13.
14.
Heydorn A, Nielsen AT, Hentzer M, Sternberg C, Molin S. Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology. 2000;146:2395–407.PubMed
15.
Tolker-Nielsen T, Brinch UC, Ragas PC, Andersen JB, Jacobsen CS, Molin S. Development and dynamics of Pseudomonas sp. biofilms. J Bacteriol. 2000;182(22):6482–9.PubMedPubMedCentral
16.
Drewes JL, White JR, Dejea CM, Fathi P, Iyadorai T, Vadivelu J, et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microb. 2017;3:34.
17.
Dejea CM, Wick EC, Hechenbleikner EM, White JR, Welch JL, Rossetti BJ, Peterson SN, Snesrud EC, Borisy GG, Lazarev M, Stein E. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Nat Acad Sci. 2014;111(51):18321–6.PubMedPubMedCentral
18.
Raskov H, Kragh KN, Bjarnsholt T, Alamili M, Gogenur I. Bacterial biofilm formation inside colonic crypts may accelerate colorectal carcinogenesis. Clin Transl Med. 2018;7(1):30.PubMedPubMedCentral
19.
Soler A, Miller R, Laughlin K, Carp N, Klurfeld D, Mullin J. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis. 1999;20(8):1425–31.PubMed
20.
Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176–82.PubMedPubMedCentral
21.
Ciofu O, Mandsberg LF, Wang H, Høiby N. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol Med Microbiol. 2012;65(2):215–25.PubMed
22.
Anderl JN, Zahller J, Roe F, Stewart PS. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother. 2003;47(4):1251–6.PubMedPubMedCentral
23.
Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother. 2003;47(1):317–23.PubMedPubMedCentral
24.
Ma H, Bryers JD. Non-invasive determination of conjugative transfer of plasmids bearing antibiotic-resistance genes in biofilm-bound bacteria: effects of substrate loading and antibiotic selection. Appl Microbiol Biotechnol. 2013;97(1):317–28.PubMed
25.
Ibrahim NH, Melake NA, Somily AM, Zakaria AS, Baddour MM, Mahmoud AZ. The effect of antifungal combination on transcripts of a subset of drug-resistance genes in clinical isolates of Candida species induced biofilms. Saudi Pharm J. 2015;23(1):55–66.PubMed
26.
Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BH, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015;21(6):891–7.PubMedPubMedCentral
27.
Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–82.PubMed
28.
Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, et al. Towards the human colorectal cancer microbiome. PLoS ONE. 2011;6(5):e20447.PubMedPubMedCentral
29.
Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.PubMed
30.
Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306.PubMedPubMedCentral
31.
Harald zur H. The search for infectious causes of human cancers: where and why. Virology. 2009;392(1):1.
32.
Boleij A, Tjalsma H. Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc. 2012;87(3):701–30.PubMed
33.
Wu S, Shin J, Zhang G, Cohen M, Franco A, Sears CL. The Bacteroides fragilis toxin binds to a specific intestinal epithelial cell receptor. Infect Immun. 2006;74(9):5382–90.PubMedPubMedCentral
34.
Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect. 2006;12(8):782–6.PubMed
35.
Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci USA. 2011;108(37):15354–9.PubMedPubMedCentral
36.
Abais JM, Xia M, Zhang Y, Boini KM, Li PL. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal. 2015;22(13):1111–29.PubMedPubMedCentral
37.
Wu S, Rhee KJ, Zhang M, Franco A, Sears CL. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretase-dependent E-cadherin cleavage. J Cell Sci. 2007;120(Pt 11):1944–52.PubMed
38.
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60.PubMedPubMedCentral
39.
Wu S, Morin PJ, Maouyo D, Sears CL. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology. 2003;124(2):392–400.PubMed
40.
Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15(9):1016–22.PubMedPubMedCentral
41.
Göktuna SI, Shostak K, Chau TL, Heukamp LC, Hennuy B, Duong HQ, et al. The prosurvival IKK-related kinase IKKε integrates LPS and IL17A signaling cascades to promote Wnt-dependent tumor development in the intestine. Can Res. 2016;76(9):2587–99.
42.
Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol. 2002;282(6):G1035–44.PubMed
43.
Swidsinski A, Weber J, Loening-Baucke V, Hale L, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43(7):3380–9.PubMedPubMedCentral
44.
Ruiz PA, Shkoda A, Kim SC, Sartor RB, Haller D. IL-10 gene-deficient mice lack TGF-beta/Smad-mediated TLR2 degradation and fail to inhibit proinflammatory gene expression in intestinal epithelial cells under conditions of chronic inflammation. Ann N Y Acad Sci. 2006;1072:389–94.PubMed
45.
Szigeti R, Pangas SA, Nagy-Szakal D, Dowd SE, Shulman RJ, Olive AP, et al. SMAD4 haploinsufficiency associates with augmented colonic inflammation in select humans and mice. Ann Clin Lab Sci. 2012;42(4):401–8.PubMedPubMedCentral
46.
Wang X, Huycke MM. Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology. 2007;132(2):551–61.PubMed
47.
McCool KW, Miyamoto S. DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunol Rev. 2012;246(1):311–26.PubMedPubMedCentral
48.
Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nat Rev Cancer. 2001;1(2):109–17.PubMed
49.
Zhou H, Ivanov VN, Gillespie J, Geard CR, Amundson SA, Brenner DJ, et al. Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway. Proc Natl Acad Sci USA. 2005;102(41):14641–6.PubMedPubMedCentral
50.
Carniol K, Gilmore MS. Signal transduction, quorum-sensing, and extracellular protease activity in Enterococcus faecalis biofilm formation. J Bacteriol. 2004;186(24):8161–3.PubMedPubMedCentral
51.
Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science (New York, NY). 2006;313(5788):848–51.
52.
Allen-Vercoe E, Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC. Immunol Lett. 2014;162:54–61.PubMedPubMedCentral
53.
Leung A, Tsoi H, Yu J. Fusobacterium and Escherichia: models of colorectal cancer driven by microbiota and the utility of microbiota in colorectal cancer screening. Expert Rev Gastroenterol Hepatol. 2015;9(5):651–7.PubMed
54.
Maddocks OD, Scanlon KM, Donnenberg MS. An Escherichia coli effector protein promotes host mutation via depletion of DNA mismatch repair proteins. mBio. 2013;4(3):e00152-e213.PubMedPubMedCentral
55.
Housseau F, Sears CL. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell cycle (Georgetown, Tex). 2010;9(1):3–5.
56.
Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microb. 2010;1(3):138–47.
57.
Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Can Res. 2009;69(11):4918–25.
58.
Cao H, Luo S, Xu M, Zhang Y, Song S, Wang S, et al. The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apc (min/+) mice through enhancing Wnt signaling. Fam Cancer. 2014;13(4):563–71.PubMed
59.
Belcheva A, Irrazabal T, Robertson SJ, Streutker C, Maughan H, Rubino S, et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell. 2014;158(2):288–99.PubMed
60.
den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol. 2013;305(12):G900–10.
61.
Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA. 2014;111(6):2247–52.PubMedPubMedCentral
62.
Kim CH, Park J, Kim M. Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immun Netw. 2014;14(6):277–88.
63.
Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Can Res. 1994;54(12):3288–93.
64.
Biarc J, Nguyen IS, Pini A, Gossé F, Richert S, Thiersé D, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S. bovis). Carcinogenesis. 2004;25(8):1477–84.PubMed
65.
Abdulamir AS, Hafidh RR, Abu BF. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res CR. 2011;30(1):11.PubMed
66.
Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994;305(2):253–64.PubMed
67.
Abdulamir AS, Hafidh RR, Bakar FA. Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer. 2010;9:249.PubMedPubMedCentral
68.
Deng Q, Wang C, Yu K, Wang Y, Yang Q, Zhang J, et al. Streptococcus bovis contributes to the development of colorectal cancer via recruiting CD11b+ TLR-4+ Cells. Med Sci Monit. 2020;26:e921886.PubMedPubMedCentral
69.
Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis. 2011;53(9):870–8.PubMed
70.
Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2011;55(9):4469–74.PubMedPubMedCentral
71.
Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56(5):2683–90.PubMedPubMedCentral
72.
Hussain A, Alajmi MF, Khan MA, Pervez SA, Ahmed F, Amir S, et al. Biosynthesized Silver Nanoparticle (AgNP) from pandanus odorifer leaf extract exhibits anti-metastasis and anti-biofilm potentials. Front Microbiol. 2019;10:8.PubMedPubMedCentral
73.
Gopinath K, Kumaraguru S, Bhakyaraj K, Mohan S, Venkatesh KS, Esakkirajan M, et al. Green synthesis of silver, gold and silver/gold bimetallic nanoparticles using the Gloriosa superba leaf extract and their antibacterial and antibiofilm activities. Microb Pathog. 2016;101:1–11.PubMed
74.
Singh R, Dumlupinar G, Andersson-Engels S, Melgar S. Emerging applications of upconverting nanoparticles in intestinal infection and colorectal cancer. Int J Nanomed. 2019;14:1027–38.
75.
Nayak M, Singh AK, Prakash P, Kant R, Bhattacharya S. Structural studies on thiosalicylate complexes of Zn (II) & Hg (II). First insight into Zn (II)-thiosalicylate complex as potential antibacterial, antibiofilm and anti-tumour agent. Inorg Chim Acta. 2020;501:119263.
76.
77.
Sambanthamoorthy K, Luo C, Pattabiraman N, Feng X, Koestler B, Waters CM, et al. Identification of small molecules inhibiting diguanylate cyclases to control bacterial biofilm development. Biofouling. 2014;30(1–2):17–28.PubMed
78.
79.
Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci. 2009;66(23):3821–6.PubMed
80.
81.
Vizán J, Hernandez-Chico CI, Castillo ID, Moreno F. The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase. The EMBO journal. 1999;10(2):467–76.
82.
Kharidia R, Liang J. The activity of a small lytic peptide PTP-7 on Staphylococcus aureus biofilms. J Microbiol. 2011;49(4):663–8.PubMed
83.
Overhage J, Campisano A, Bains M, Torfs E, Hancock R. Immunity human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76(9):4176–82.PubMedPubMedCentral
84.
Boman HG. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun. 1993;61(7):2978–84.PubMedPubMedCentral
85.
Hsu CH, Chen C, Jou ML, Lee YL, Wu SH. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res. 2005;33(13):4053–64.PubMedPubMedCentral
86.
Ju HC, Sung BH, Sun CK. Buforins: histone H2A-derived antimicrobial peptides from toad stomach. Biochim BiophysActa Biomembr. 2009;1788(8):1564–9.
87.
Ma DSL, Tan LT, Chan KG, Yap WH, Pusparajah P, Chuah LH, et al. Resveratrol-potential antibacterial agent against foodborne pathogens. Front Pharmacol. 2018;9:102.PubMedPubMedCentral
88.
Santosh Kumar SC, Srinivas P, Negi PS, Bettadaiah BK. Antibacterial and antimutagenic activities of novel zerumbone analogues. Food Chem. 2013;141(2):1097–103.PubMed
89.
Haque MA, Jantan I, Arshad L, Bukhari SNA. Exploring the immunomodulatory and anticancer properties of zerumbone. Food Funct. 2017;8(10):3410–31.PubMed
90.
Kim HR, Rhee KJ, Eom YB. Anti-biofilm and antimicrobial effects of zerumbone against Bacteroides fragilis. Anaerobe. 2019;57:99–106.PubMed
91.
Jang HI, Rhee KJ, Eom YB. Antibacterial and antibiofilm effects of α-humulene against Bacteroides fragilis. Can J Microbiol. 2020;66(6):389–99.PubMed
92.
Chmit M, Kanaan H, Habib J, Abbass M, McHeik A, Chokr A. Antibacterial and antibiofilm activities of polysaccharides, essential oil, and fatty oil extracted from Laurus nobilis growing in Lebanon. Asian Pac J Trop Med. 2014;71:546–52.
93.
Bakkiyaraj D, Nandhini JR, Malathy B, Pandian SK. The anti-biofilm potential of pomegranate (Punica granatum L.) extract against human bacterial and fungal pathogens. Biofouling. 2013;29(8):929–37.PubMed
94.
Tan LT, Chan KG, Lee LH, Goh BH. Streptomyces bacteria as potential probiotics in aquaculture. Front Microbiol. 2016;7:79.PubMedPubMedCentral
95.
Shin DS, Rhee KJ, Eom YB. Effect of probiotic clostridium butyricum NCTC 7423 supernatant on biofilm formation and gene expression of Bacteroides fragilis. J Microbiol Biotechnol. 2020;30(3):368–77.PubMed
96.
Abdelhamid AG, Esaam A, Hazaa MM. Cell free preparations of probiotics exerted antibacterial and antibiofilm activities against multidrug resistant E. coli. Saudi Pharm J. 2018;26(5):603–7.PubMedPubMedCentral
97.
Mukai T, Kaneko S, Matsumoto M, Ohori H. Binding of Bifidobacterium bifidum and Lactobacillus reuteri to the carbohydrate moieties of intestinal glycolipids recognized by peanut agglutinin. Int J Food Microbiol. 2004;90(3):357–62.PubMed
98.
Barzegari A, Kheyrolahzadeh K, Hosseiniyan Khatibi SM, Sharifi S, Memar MY, Zununi VS. The battle of probiotics and their derivatives against biofilms. Infect Drug Res. 2020;13:659–72.
99.
Mahdhi A, Leban N, Chakroun I, Bayar S, Mahdouani K, Majdoub H, et al. Use of extracellular polysaccharides, secreted by Lactobacillus plantarum and Bacillus, as reducing indole production agents to control biofilm formation and efflux pumps inhibitor in Escherichia coli. Microb Pathog. 2018;125:448–53.PubMed
100.
Sharma V, Harjai K, Shukla G. Effect of bacteriocin and exopolysaccharides isolated from probiotic on P aeruginosa PAO1 biofilm. Folia Microbiol. 2018;63(2):181–90.
101.
Jiang Q, Chen J, Yang C, Yin Y, Yao K. Quorum sensing: a prospective therapeutic target for bacterial diseases. Biomed Res Int. 2019;2019:2015978.PubMedPubMedCentral
102.
103.
Walz JM, Avelar RL, Longtine KJ, Carter KL, Mermel LA, Heard SO. Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. Crit Care Med. 2010;38(11):2095–102.PubMed
104.
van Delden C, Köhler T, Brunner-Ferber F, François B, Carlet J, Pechère JC. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 2012;38(7):1118–25.PubMed
Metadaten
Titel
Bacterial driver–passenger model in biofilms: a new mechanism in the development of colorectal cancer
verfasst von
J. Xing
Y. Fang
W. Zhang
H. Zhang
D. Tang
D. Wang
Publikationsdatum
09.01.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-021-02738-y

Weitere Artikel der Ausgabe 5/2022

Clinical and Translational Oncology 5/2022 Zur Ausgabe

Review Article

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

Research Article

Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer

Research Article

Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer

Research Article

Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer

Research Article

BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system

Research Article

Analgesic effects of low-dose radiotherapy in greater trochanteric pain syndrome: results in a clinical series of 155 patients with recurrent or refractory symptoms

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise